A double-blind controlled study of clinical efficacy of maprotiline and
amitriptyline in depression
by
Watanabe S, Yokoyama S, Kubo S, Iwai H, Kuyama C
Folia Psychiatr Neurol Jpn 1978; 32(1):1-31
ABSTRACT
A multiclinic double-blind controlled study was performed on the effects of
MAP in both inpatients and outpatients with AMT as control drug. 1. Subjects
consisted of 41 male and 45 female patients suffering from various types of
depression. MAP was assigned to 42 cases and AMT to 44 cases. Of these patients,
14 MAP cases and 10 AMT cases were subsequently dropped for a variety of reasons
to obtain 28 MAP cases and 34 AMT cases as evaluable. 2. The global improvement
ratings were compared and found not significantly different for any week between
the two treatments. 3. The global improvement ratings by the characteristic
features of patients did not show any significant difference in any items
studied between the two treatments. 4. The symptomatic improvement ratings (on
the Hamilton R.S. for assessment by the physician) indicated that AMT was more
effective on "anxiety (psychic)." 5. The symptomatic improvement ratings (on the
Beck self-assessment scale by the patient) indicated that MAP was more effective
on "work" and AMT on "pathos", "feeling of satisfaction", "withdrawal" and "loss
of libido." 6. During the treament period, 74.3 percent of the MAP group and
76.9 percent of the AMT group of patients showed some side effects of
accompanying symptoms, with no significant difference recognized between the two
treatments. Itemwise, however, the incidence of tremor was significantly lower
(p-=0.06) in the MAP group. Moreover, the MAP group tended to be less liable to
such anticholinergic side effects as dry mouth, constipation, trouble of
accomodation, urinary disturbance and palpitation. 7. On the basis of the above
findings, it is concluded that MAP is as effective against depression as AMT and
less liable to the anticholinergic side effects. It is, therefore, a very useful
antidepressant.
SSRIs
Options
Reboxetine
Amineptine
Dumb Drugs
Desipramine
Amitriptyline
TCAs v SSRIs
Norepinephrine
Antidepressant toxicity
Maprotiline versus mianserin
Maprotiline versus paroxetine
Maprotiline versus amineptine
Maprotiline versus amitriptiline
Maprotiline versus fluvoxamine
Refs
HOME
HedWeb
Cocaine.org
Future Opioids
BLTC Research
Superhappiness?
Paradise-Engineering
The Abolitionist Project
The Hedonistic Imperative
MDMA: Utopian Pharmacology

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family